Literature DB >> 1612330

Hemodynamic evaluation of octreotide in patients with hepatitis B-related cirrhosis.

H C Lin1, Y T Tsai, F Y Lee, S D Lee, H C Hsia, W J Lin, K J Lo.   

Abstract

The hemodynamic effects of octreotide were studied in 20 patients with hepatitis B-related cirrhosis. In patients receiving a 100-micrograms bolus and a 100-micrograms/h infusion, heart rate, cardiac index, and systemic vascular resistance showed no significant changes, whereas right atrial pressure, pulmonary capillary wedge pressure, and inferior vena cava pressure decreased significantly after octreotide infusion compared with basal values. In contrast, in patients receiving a 50-micrograms bolus and a 50-micrograms/h infusion, all the systemic hemodynamic values were unaffected. In both groups of patients receiving two different doses of octreotide, the estimated hepatic blood flow, hepatic indocyanine green clearance, and wedge hepatic venous pressure were significantly reduced at 60 minutes after octreotide administration compared with basal values, whereas the hepatic venous pressure gradient remained unchanged. It is concluded that the two different doses of octreotide administration result in the reduction of the wedge hepatic venous pressure and the hepatic blood flow of a similar magnitude, whereas the hepatic venous pressure gradient is unaffected. Octreotide induces discrepant systemic hemodynamic response; this effect is dose related.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1612330     DOI: 10.1016/0016-5085(92)91117-m

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  8 in total

1.  Hemodynamic effects of eight-day octreotide and propranolol administration in portal hypertensive rats.

Authors:  Y T Huang; Y R Cheng; H C Lin; M C Hou; S D Lee; C Y Hong
Journal:  Dig Dis Sci       Date:  1998-02       Impact factor: 3.199

2.  Sildenafil decreased pulmonary arterial pressure but may have exacerbated portal hypertension in a patient with cirrhosis and portopulmonary hypertension.

Authors:  Ying-Wen Wang; Han-Chieh Lin; Ying-Ying Yang; Ming-Chih Hou; Shou-Dong Lee
Journal:  J Gastroenterol       Date:  2006-06       Impact factor: 7.527

Review 3.  When endoscopic therapy or pharmacotherapy fails to control variceal bleeding: what should be done? Immediate control of bleeding by TIPS?

Authors:  Martin Rössle
Journal:  Langenbecks Arch Surg       Date:  2003-05-01       Impact factor: 3.445

4.  Assessment of variceal pressure by continuous non-invasive endoscopic registration: a placebo controlled evaluation of the effect of terlipressin and octreotide.

Authors:  F Nevens; W Van Steenbergen; S H Yap; J Fevery
Journal:  Gut       Date:  1996-01       Impact factor: 23.059

5.  Effects of octreotide on lower esophageal sphincter in patients with cirrhosis and portal hypertension.

Authors:  T Barrioz; C Borderie; P Strock; P Ingrand; E Fort; C Silvain; M Beauchant
Journal:  Dig Dis Sci       Date:  1998-07       Impact factor: 3.199

6.  Increased plasma malondialdehyde in patients with viral cirrhosis and its relationships to plasma nitric oxide, endotoxin, and portal pressure.

Authors:  Kuei-Chuan Lee; Ying-Ying Yang; Ying-Wen Wang; Fa-Yauh Lee; Che-Chuan Loong; Ming-Chih Hou; Han-Chieh Lin; Shou-Dong Lee
Journal:  Dig Dis Sci       Date:  2009-10-14       Impact factor: 3.199

7.  Octreotide versus terlypressin in acute variceal hemorrhage in liver cirrhosis. Emergency control and prevention of early rebleeding.

Authors:  G Pedretti; G Elia; C Calzetti; G Magnani; F Fiaccadori
Journal:  Clin Investig       Date:  1994-09

Review 8.  Management of portal hypertension and ascites in polycystic liver disease.

Authors:  Lucas H P Bernts; Joost P H Drenth; Eric T T L Tjwa
Journal:  Liver Int       Date:  2019-09-20       Impact factor: 5.828

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.